Side-by-side · Research reference

AdipotidevsGHRP-6

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BPhase 1HUMAN-REVIEWED10/36 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Adipotide

GHRP-6

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Ghrelin receptor (GHS-R1a)Bowers 1990

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

—

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

GHRP-6

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

—

Frequency

Not specified in available data

1–3× per day

Evidence basis

Preclinical animal models only

Phase 1 + clinical practiceBowers 1990

Human data

None — no clinical trials reported

—

Standard dose

—

100–200 mcg per injectionBowers 1990

Lower / starter dose

—

50 mcg per dose

Duration

—

8–12 weeks on / 4 off

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-meal preferred for appetite support

Half-life

—

~15 minMalagón 1999

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

GHRP-6

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

GHRP-6

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Hunger

—

Pronounced — defining feature vs ipamorelin

Cortisol elevation

—

Mild

Prolactin elevation

—

Mild

Injection site reaction

—

Mild

Cancer risk

—

Contraindicated in active malignancy

Pregnancy / OB

—

Avoid

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

05Administration Protocol

Parameter

Adipotide

GHRP-6

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

SQ — abdomen. Rotate sites.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Pre-meal for appetite support; pre-sleep for GH alignment.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.